Figure 1 | Scientific Reports

Figure 1

From: Pan-cancer analysis revealing that PTPN2 is an indicator of risk stratification for acute myeloid leukemia

Figure 1

Pan-cancer analysis of PTPNs. (a) Differential expression of PTPNs. (b) The constitute of the Heterozygous/Homozygous CNV of PTPNs in pan-cancer. (c) The mutation distribution of the top 10 mutated genes in PTPNs and a SNV classification of SNV types. (d) The percentage of cancers in which PTPNs expression has potential effect (FDR <  = 0.05) on pathway activity. (e) Priority of PTPNs among four immunosuppressive indices, including the T-cell dysfunction levels, ICB response outcome, phenotypes in CRISPR screens, and T-cell exclusion cell types. (f) Correlation between PTPNs expression and drug IC50.

Back to article page